efficacy and safety of ibandronic acid administered intravenously to juvenile arthritis patients with severe system osteoporosis

Clicks: 141
ID: 164980
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract

The article is dedicated to study of efficacy and safety of ibandronic acid administered intravenously to 25 patients suffering from juvenile arthritis and system osteoporosis. It was concluded that administration of 3 mg of ibandronate every 3 months during 76 weeks increase  CTX, which indicates improvement of bone metabolism. During the treatment no subsequent vertebrae fractures have been registered. Increase in bone mass during the ibandronate therapy has been sufficient to allow endoprosthetic hip replacement in 7 patients.

Key words: child, juvenile arthritis, osteoporosis, treatment, biophosphates, ibandronic acid.
(Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (6): 83–88)

Reference Key
denisova2011voprosyefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;R.V. Denisova;E.I. Alexeeva;V.G. Pinelis;M.I. Bakanov;S.I. Valieva;T.M. Bzarova;K.B. Isaeva;S.Yu. Morev;G.V. Kuznetsova
Journal Biocontrol science
Year 2011
DOI
DOI not found
URL
http://vsp.spr-journal.ru:80/jour/article/view/780
Keywords
child treatment osteoporosis juvenile arthritis ibandronic acidpediatrics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.